[1]
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006 Jun:69(11):1945-53
[PubMed PMID: 16641930]
[2]
Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W, Nessel L, Anderson AH, Lo J, Porter A, Nunes JW, Negrea L, Hamm L, Horwitz E, Chen J, Scialla JJ, de Boer IH, Leonard MB, Feldman HI, Wolf M, CRIC Study Investigators. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2020 Feb:75(2):235-244. doi: 10.1053/j.ajkd.2019.07.022. Epub 2019 Oct 23
[PubMed PMID: 31668375]
[3]
Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney international. 2014 Jan:85(1):142-50. doi: 10.1038/ki.2013.271. Epub 2013 Jul 24
[PubMed PMID: 23884339]
[4]
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). The Cochrane database of systematic reviews. 2018 Aug 22:8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Epub 2018 Aug 22
[PubMed PMID: 30132304]
Level 1 (high-level) evidence
[5]
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney international. 2017 Jul:92(1):26-36. doi: 10.1016/j.kint.2017.04.006. Epub
[PubMed PMID: 28646995]
[6]
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clinical journal of the American Society of Nephrology : CJASN. 2011 Apr:6(4):913-21. doi: 10.2215/CJN.06040710. Epub 2011 Mar 31
[PubMed PMID: 21454719]
[7]
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Journal of the American Society of Nephrology : JASN. 2005 Jul:16(7):2205-15
[PubMed PMID: 15917335]
[8]
Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Seminars in nephrology. 2002 Nov:22(6):488-93
[PubMed PMID: 12430093]
[9]
Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood purification. 2003:21(4-5):318-26
[PubMed PMID: 12944733]
[10]
Georgiadou E, Marketou H, Trovas G, Dontas I, Papaioannou N, Makris K, Galanos A, Papavassiliou AG. Effect of Calcitriol on FGF23 Level in Healthy Adults and its Dependence on Phosphate Level. In vivo (Athens, Greece). 2017 Jan 2:31(1):145-150
[PubMed PMID: 28064234]
[11]
Yamada S, Tsuruya K, Kitazono T, Nakano T. Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis. Clinical and experimental nephrology. 2022 Jul:26(7):613-629. doi: 10.1007/s10157-022-02216-x. Epub 2022 Mar 30
[PubMed PMID: 35353283]
[12]
Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1995 May:25(5):663-79
[PubMed PMID: 7747720]
[13]
Bricker NS. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". The New England journal of medicine. 1972 May 18:286(20):1093-9
[PubMed PMID: 4553202]
[14]
Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH--double agents at the heart of CKD. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 May:27(5):1715-20. doi: 10.1093/ndt/gfs050. Epub 2012 Mar 23
[PubMed PMID: 22447519]
[15]
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney international. 2011 Jun:79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9
[PubMed PMID: 21389978]
[16]
Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clinical journal of the American Society of Nephrology : CJASN. 2010 Jan:5(1):110-6. doi: 10.2215/CJN.03630509. Epub 2009 Nov 5
[PubMed PMID: 19965548]
[17]
Paloian NJ, Giachelli CM. A current understanding of vascular calcification in CKD. American journal of physiology. Renal physiology. 2014 Oct 15:307(8):F891-900. doi: 10.1152/ajprenal.00163.2014. Epub 2014 Aug 20
[PubMed PMID: 25143458]
Level 3 (low-level) evidence
[18]
Courbebaisse M, Lanske B. Biology of Fibroblast Growth Factor 23: From Physiology to Pathology. Cold Spring Harbor perspectives in medicine. 2018 May 1:8(5):. doi: 10.1101/cshperspect.a031260. Epub 2018 May 1
[PubMed PMID: 28778965]
Level 3 (low-level) evidence
[19]
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. The Journal of clinical investigation. 1984 Dec:74(6):2136-43
[PubMed PMID: 6549016]
[20]
Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. American journal of physiology. Renal physiology. 2005 Feb:288(2):F253-64
[PubMed PMID: 15507543]
[21]
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1998 Apr:31(4):607-17
[PubMed PMID: 9531176]
[22]
Quinn SJ, Thomsen AR, Pang JL, Kantham L, Bräuner-Osborne H, Pollak M, Goltzman D, Brown EM. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. American journal of physiology. Endocrinology and metabolism. 2013 Feb 1:304(3):E310-20. doi: 10.1152/ajpendo.00460.2012. Epub 2012 Dec 11
[PubMed PMID: 23233539]
[23]
Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney international. 2004 May:65(5):1943-6
[PubMed PMID: 15086938]
[24]
Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. The Journal of biological chemistry. 2003 Jan 24:278(4):2206-11
[PubMed PMID: 12419819]
[25]
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. The Journal of clinical investigation. 2007 Dec:117(12):4003-8
[PubMed PMID: 17992255]
[26]
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006 Dec 7:444(7120):770-4
[PubMed PMID: 17086194]
[27]
Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contributions to nephrology. 2013:180():47-63. doi: 10.1159/000346778. Epub 2013 May 3
[PubMed PMID: 23652549]
[28]
Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2000 Feb:15(2):218-23
[PubMed PMID: 10648668]
[29]
Qunibi WY, Abouzahr F, Mizani MR, Nolan CR, Arya R, Hunt KJ. Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney international. 2005 Jul:68(1):271-7
[PubMed PMID: 15954917]
[30]
Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI, CRIC Study Investigators. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011 Oct:58(4):519-26. doi: 10.1053/j.ajkd.2011.04.024. Epub 2011 Jul 23
[PubMed PMID: 21783289]
[31]
Chuang SH, Wong HC, Vathsala A, Lee E, How PP. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Singapore medical journal. 2016 Nov:57(11):603-609. doi: 10.11622/smedj.2015195. Epub 2015 Dec 29
[PubMed PMID: 26778726]
[32]
Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L, Bone Turnover Work Group. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2004 Mar:43(3):558-65
[PubMed PMID: 14981615]
[33]
Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney international. 1994 Oct:46(4):1160-6
[PubMed PMID: 7861712]
[34]
Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D. Renal osteodystrophy in diabetic patients. Kidney international. 1993 Jul:44(1):159-64
[PubMed PMID: 8355457]
[35]
Moe SM, Drüeke TB. A bridge to improving healthcare outcomes and quality of life. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2004 Mar:43(3):552-7
[PubMed PMID: 14981614]
Level 2 (mid-level) evidence
[36]
D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney international. Supplement. 2003 Jun:(85):S73-8
[PubMed PMID: 12753271]
Level 2 (mid-level) evidence
[37]
Leifheit-Nestler M, Haffner D. How FGF23 shapes multiple organs in chronic kidney disease. Molecular and cellular pediatrics. 2021 Sep 18:8(1):12. doi: 10.1186/s40348-021-00123-x. Epub 2021 Sep 18
[PubMed PMID: 34536161]
[38]
Hruska KA, Teitelbaum SL. Renal osteodystrophy. The New England journal of medicine. 1995 Jul 20:333(3):166-74
[PubMed PMID: 7791820]
[40]
Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. The Journal of clinical investigation. 1995 Oct:96(4):1786-93
[PubMed PMID: 7560070]
[41]
Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2002 Dec:17(12):2094-105
[PubMed PMID: 12469904]
Level 3 (low-level) evidence
[42]
Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT plus. 2008 Jun:1(3):135-47. doi: 10.1093/ndtplus/sfn040. Epub
[PubMed PMID: 25983860]
[43]
Stathi D, Fountoulakis N, Panagiotou A, Maltese G, Corcillo A, Mangelis A, Ayis S, Gnudi L, Karalliedde J. Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease. Bone. 2023 Jan:166():116581. doi: 10.1016/j.bone.2022.116581. Epub 2022 Oct 8
[PubMed PMID: 36216304]
[44]
Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney international. 1990 Jun:37(6):1522-7
[PubMed PMID: 2194068]
[45]
Viegas CSB, Santos L, Macedo AL, Matos AA, Silva AP, Neves PL, Staes A, Gevaert K, Morais R, Vermeer C, Schurgers L, Simes DC. Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification: A Role for GRP (Gla-Rich Protein). Arteriosclerosis, thrombosis, and vascular biology. 2018 Mar:38(3):575-587. doi: 10.1161/ATVBAHA.117.310578. Epub 2018 Jan 4
[PubMed PMID: 29301790]
[46]
Köppert S, Büscher A, Babler A, Ghallab A, Buhl EM, Latz E, Hengstler JG, Smith ER, Jahnen-Dechent W. Cellular Clearance and Biological Activity of Calciprotein Particles Depend on Their Maturation State and Crystallinity. Frontiers in immunology. 2018:9():1991. doi: 10.3389/fimmu.2018.01991. Epub 2018 Sep 4
[PubMed PMID: 30233585]
[47]
Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. Journal of atherosclerosis and thrombosis. 2023 Aug 1:30(8):835-850. doi: 10.5551/jat.RV22006. Epub 2023 May 30
[PubMed PMID: 37258233]
[48]
Xie J, Yoon J, An SW, Kuro-o M, Huang CL. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. Journal of the American Society of Nephrology : JASN. 2015 May:26(5):1150-60. doi: 10.1681/ASN.2014040325. Epub 2014 Dec 4
[PubMed PMID: 25475745]
[49]
McGrath ER, Himali JJ, Levy D, Conner SC, Pase MP, Abraham CR, Courchesne P, Satizabal CL, Vasan RS, Beiser AS, Seshadri S. Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PloS one. 2019:14(3):e0213321. doi: 10.1371/journal.pone.0213321. Epub 2019 Mar 4
[PubMed PMID: 30830941]
[50]
Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, Fujimi S, Kitazono T. Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis: The Q-Cohort Study. Stroke. 2016 Sep:47(9):2189-96. doi: 10.1161/STROKEAHA.116.013195. Epub 2016 Aug 9
[PubMed PMID: 27507862]
[51]
Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, Iseki K, Tsubakihara Y. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PloS one. 2014:9(12):e114678. doi: 10.1371/journal.pone.0114678. Epub 2014 Dec 10
[PubMed PMID: 25494334]
[52]
Yang X, Cai S, Gong J, Zhang J, Lian M, Chen R, Zhou L, Bai P, Liu B, Zhuang M, Tan H, Xu J, Li M. Characterization of gut microbiota in patients with stage 3-4 chronic kidney disease: a retrospective cohort study. International urology and nephrology. 2024 May:56(5):1751-1762. doi: 10.1007/s11255-023-03893-7. Epub 2023 Dec 12
[PubMed PMID: 38085410]
Level 2 (mid-level) evidence
[53]
Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B, Sanchez-Niño MD. Phosphate, Microbiota and CKD. Nutrients. 2021 Apr 13:13(4):. doi: 10.3390/nu13041273. Epub 2021 Apr 13
[PubMed PMID: 33924419]
[54]
Cernaro V, Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Spinella C, Gembillo G, Santoro D. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert opinion on pharmacotherapy. 2023 Sep-Dec:24(15):1737-1746. doi: 10.1080/14656566.2023.2243817. Epub 2023 Aug 11
[PubMed PMID: 37527180]
Level 3 (low-level) evidence
[55]
Yamada S, Arase H, Tokumoto M, Taniguchi M, Yoshida H, Nakano T, Tsuruya K, Kitazono T. Increased Risk of Infection-Related and All-Cause Death in Hypercalcemic Patients Receiving Hemodialysis: The Q-Cohort Study. Scientific reports. 2020 Apr 14:10(1):6327. doi: 10.1038/s41598-020-63334-8. Epub 2020 Apr 14
[PubMed PMID: 32286455]
[56]
Zheng L, Hunter K, Gaughan J, Poddar S. Preadmission Use of Calcium Channel Blockers and Outcomes After Hospitalization With Pneumonia: A Retrospective Propensity-Matched Cohort Study. American journal of therapeutics. 2017 Jan/Feb:24(1):e30-e38. doi: 10.1097/MJT.0000000000000312. Epub
[PubMed PMID: 26280292]
Level 2 (mid-level) evidence
[57]
Wiewel MA, van Vught LA, Scicluna BP, Hoogendijk AJ, Frencken JF, Zwinderman AH, Horn J, Cremer OL, Bonten MJ, Schultz MJ, van der Poll T, Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium. Prior Use of Calcium Channel Blockers Is Associated With Decreased Mortality in Critically Ill Patients With Sepsis: A Prospective Observational Study. Critical care medicine. 2017 Mar:45(3):454-463. doi: 10.1097/CCM.0000000000002236. Epub
[PubMed PMID: 28079604]
Level 2 (mid-level) evidence
[58]
Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, Evenepoel P, Christensson A, Zhao X, Alrukhaimi M, Al-Ali F, Young EW, Robinson BM, Fukagawa M. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. Journal of cachexia, sarcopenia and muscle. 2021 Aug:12(4):855-865. doi: 10.1002/jcsm.12722. Epub 2021 Jun 1
[PubMed PMID: 34060245]
[60]
Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clinical nephrology. 1988 Aug:30(2):57-62
[PubMed PMID: 3180516]
[61]
Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney international. 1994 Sep:46(3):855-61
[PubMed PMID: 7996807]
[62]
Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart (British Cardiac Society). 2013 Mar:99(6):365-72. doi: 10.1136/heartjnl-2012-302818. Epub 2012 Oct 31
[PubMed PMID: 23118349]
[64]
Kemper MJ, van Husen M. Renal osteodystrophy in children: pathogenesis, diagnosis and treatment. Current opinion in pediatrics. 2014 Apr:26(2):180-6. doi: 10.1097/MOP.0000000000000061. Epub
[PubMed PMID: 24553631]
Level 3 (low-level) evidence
[65]
Esfahani DR, Alaraj A, Birk DM, Thulborn KR, Charbel FT. Stenosis Before Thrombosis: Intracranial Hypertension from Jugular Foramen Stenosis Secondary to Renal Osteodystrophy. World neurosurgery. 2018 Jan:109():129-133. doi: 10.1016/j.wneu.2017.09.106. Epub 2017 Sep 23
[PubMed PMID: 28951273]
[66]
Donoso-Hofer F, Gunther-Wood M, Romero-Romano P, Pezoa-Opazo N, Fernández-Toro MA, Ortega-Pinto AV. Uremic leontiasis ossea, a rare presentation of severe renal osteodystrophy secondary to hyperparathyroidism. Journal of stomatology, oral and maxillofacial surgery. 2018 Feb:119(1):56-60. doi: 10.1016/j.jormas.2017.10.006. Epub 2017 Oct 14
[PubMed PMID: 29037869]
[67]
Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. European journal of clinical investigation. 2006 Aug:36 Suppl 2():13-22
[PubMed PMID: 16884394]
[68]
Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Annals of clinical biochemistry. 2014 Mar:51(Pt 2):203-27. doi: 10.1177/0004563213510708. Epub 2013 Nov 22
[PubMed PMID: 24269946]
[69]
Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D'Haese PC, Drüeke TB, Du H, Manley T, Rojas E, Moe SM. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2016 Apr:67(4):559-66. doi: 10.1053/j.ajkd.2015.06.023. Epub 2015 Aug 25
[PubMed PMID: 26321176]
[70]
Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR, Moe SM. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. American journal of nephrology. 2014:40(6):582-91. doi: 10.1159/000371498. Epub 2015 Jan 20
[PubMed PMID: 25613675]
[71]
Meng L, Fu B. Practical use of sevelamer in chronic kidney disease patients on dialysis in People's Republic of China. Therapeutics and clinical risk management. 2015:11():705-12. doi: 10.2147/TCRM.S64657. Epub 2015 Apr 30
[PubMed PMID: 25995642]
[72]
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2003 Oct:42(4 Suppl 3):S1-201
[PubMed PMID: 14520607]
Level 2 (mid-level) evidence
[73]
Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney international. 2013 May:83(5):959-66. doi: 10.1038/ki.2012.403. Epub 2012 Dec 19
[PubMed PMID: 23254903]
[74]
Kramer H, Berns JS, Choi MJ, Martin K, Rocco MV. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014 Oct:64(4):499-509. doi: 10.1053/j.ajkd.2014.05.018. Epub 2014 Jul 28
[PubMed PMID: 25082101]
Level 2 (mid-level) evidence
[75]
Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clinical journal of the American Society of Nephrology : CJASN. 2011 Jan:6(1):50-62. doi: 10.2215/CJN.03940510. Epub 2010 Sep 28
[PubMed PMID: 20876671]
Level 1 (high-level) evidence
[76]
Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. Journal of the American Society of Nephrology : JASN. 2014 Jan:25(1):175-86. doi: 10.1681/ASN.2013010103. Epub 2013 Sep 19
[PubMed PMID: 24052631]
Level 2 (mid-level) evidence
[77]
Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012 Feb 15:307(7):674-84. doi: 10.1001/jama.2012.120. Epub
[PubMed PMID: 22337679]
Level 1 (high-level) evidence
[78]
Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney international. Supplement. 1992 Oct:38():S43-9
[PubMed PMID: 1405381]
[79]
Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009 Feb:53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24
[PubMed PMID: 19110359]
Level 1 (high-level) evidence
[80]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement. 2009 Aug:(113):S1-130. doi: 10.1038/ki.2009.188. Epub
[PubMed PMID: 19644521]
Level 1 (high-level) evidence
[81]
McCann L. K/DOQI practice guidelines for bone metabolism and disease in chronic kidney disease: another opportunity for renal dietitians to take a leadership role in improving outcomes for patients with chronic kidney disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2005 Apr:15(2):265-74
[PubMed PMID: 15827902]
Level 1 (high-level) evidence
[82]
Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011 Mar 16:305(11):1119-27. doi: 10.1001/jama.2011.308. Epub
[PubMed PMID: 21406649]
Level 1 (high-level) evidence
[83]
Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF, Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. Journal of the American Society of Nephrology : JASN. 2006 Mar:17(3 Suppl 1):S1-27
[PubMed PMID: 16497879]
Level 1 (high-level) evidence
[84]
Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011 Jun:26(6):1948-55. doi: 10.1093/ndt/gfq219. Epub 2010 Apr 25
[PubMed PMID: 20466670]
[85]
Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology : JASN. 2008 Feb:19(2):405-12. doi: 10.1681/ASN.2006101089. Epub 2008 Jan 16
[PubMed PMID: 18199805]
[86]
Mailliez S, Shahapuni I, Lecaque C, Massy ZA, Choukroun G, Fournier A. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney international. 2008 Aug:74(3):389; author reply 389. doi: 10.1038/ki.2008.168. Epub
[PubMed PMID: 18626498]
[87]
Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M, Wissing KM, Nortier JL. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014 Nov:64(5):696-705. doi: 10.1053/j.ajkd.2014.04.020. Epub 2014 May 22
[PubMed PMID: 24856872]
Level 1 (high-level) evidence
[88]
Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1996 Nov:28(5):704-12
[PubMed PMID: 9158208]
[89]
Sakaguchi T, Akizawa T. [K/DOQI clinical practice guidelines for bone metabolism and disease in CKD]. Clinical calcium. 2004 Sep:14(9):9-14
[PubMed PMID: 15577103]
Level 1 (high-level) evidence
[90]
Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney international. 1988 Dec:34(6):840-4
[PubMed PMID: 3210546]
[91]
Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2020 Sep:76(3):321-330. doi: 10.1053/j.ajkd.2020.02.439. Epub 2020 May 28
[PubMed PMID: 32475604]
Level 1 (high-level) evidence
[92]
Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clinical journal of the American Society of Nephrology : CJASN. 2008 Jan:3(1):36-45. doi: 10.2215/CJN.03591006. Epub
[PubMed PMID: 18178780]
[93]
Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS medicine. 2013:10(4):e1001436. doi: 10.1371/journal.pmed.1001436. Epub 2013 Apr 30
[PubMed PMID: 23637579]
Level 1 (high-level) evidence
[94]
Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American journal of kidney diseases : the official journal of the National Kidney Foundation. 2004 Nov:44(5 Suppl 2):34-8
[PubMed PMID: 15486872]
[95]
London GM. Bone-vascular axis in chronic kidney disease: a reality? Clinical journal of the American Society of Nephrology : CJASN. 2009 Feb:4(2):254-7. doi: 10.2215/CJN.06661208. Epub 2009 Jan 28
[PubMed PMID: 19176792]
[96]
Fujii H, Joki N. Mineral metabolism and cardiovascular disease in CKD. Clinical and experimental nephrology. 2017 Mar:21(Suppl 1):53-63. doi: 10.1007/s10157-016-1363-8. Epub 2017 Jan 6
[PubMed PMID: 28062938]
[97]
Li C, Chen XM, Li Y, Zhou YL, Yan JN, Du XG. Factors and Outcome of Renal Osteodystrophy-Associated Initial Fragility Fracture in End-Stage Renal Disease Patients. Kidney diseases (Basel, Switzerland). 2019 Mar:5(2):118-125. doi: 10.1159/000494924. Epub 2019 Feb 6
[PubMed PMID: 31019925]
[98]
Aparicio M, Lafage MH, Combe C, de Precigout V, Bouchet JL, Potaux L. Low-protein diet and renal osteodystrophy. Nephron. 1991:58(2):250-2
[PubMed PMID: 1865990]
[99]
Ghimire S, Lee K, Jose MD, Castelino RL, Zaidi STR. Adherence assessment practices in haemodialysis settings: A qualitative exploration of nurses and pharmacists' perspectives. Journal of clinical nursing. 2019 Jun:28(11-12):2197-2205. doi: 10.1111/jocn.14821. Epub 2019 Mar 12
[PubMed PMID: 30786082]
Level 2 (mid-level) evidence